CFO of Lexeo Therapeutics Executes Routine Insider Trade: Buys 12,000 Shares, Sells 4,641 Later for Tax‑Planning, Leaving Net Holding Strong Amid Volatile Stock Price.
Lexeo CFO’s recent buy‑sell trade shows routine tax‑planning, not a warning sign – insider liquidity moves, gene‑therapy outlook, and future investor clues.
4 minutes to read
